News
-
Rocket Science Health announced that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 12,569,658, titled “Dual Nozzles For Insertion Into Paired Body Orifices (e.g., Nasal Passages, Etc.)” covering the company’s intranasal… Read more . . .
-
Vistagen announced that it has received a “study may proceed” letter from the FDA in response to the company’s IND for a Phase 2 trial of refisolone nasal spray for the treatment of hot flashes caused… Read more . . .
-
Savara has announced that the FDA is giving itself extra time to review the company’s BLA for molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis, setting November 22, 2026 as the new… Read more . . .
-
ARS Pharmaceuticals and ALK announced that Canadian regulators have approved a 2 mg dose of neffy epinephrine nasal spray for the treatment of anaphylaxis in adults and children who weigh at least 30 kg. The… Read more . . .
-
Amneal Pharmaceuticals has announced the launch of a generic beclomethasone MDI and a generic albuterol MDI in the US, noting that these are its first metered dose inhalers in the US market. The company had… Read more . . .
-
DPI developer Iconovo has announced that interim CEO Anders Månsson will be the company’s permanent CEO. Månsson was named interim CEO at the end of October 2025, afterJohan Wäborg announced that he would step down. He had… Read more . . .
-
Oragenics said that it has initiated a Phase 2a trial of ONP-002, a dry powder intranasal neurosteroid, for the treatment of mild traumatic brain injury in Australia after receiving approval from the Human Research Ethics… Read more . . .
-
Device company Nemera and UK-based pharma company Therakind have announced a deal that will allow Nemera to add Therakind’s DriDose intranasal dry powder delivery technology to its portfolio. Therakind, which is developing several nasal DPI products… Read more . . .
-
According to Savara, the MHRA has accepted the company’s marketing application for Molbreevi molgramostim inhalation solution for the treatment of autoimmune pulmonary alveolar proteinosis for accelerated review, with a decision expected by the end of… Read more . . .
-
Glenmark Pharmaceuticals announced that it will now directly commercialize and distribute Ryaltris olopatadine / mometasone nasal spray in the US. Hikma acquired US rights to Ryaltris in February 2020 and launched the nasal spray in the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
May 10-May 14: RDD 2026, Phoenix, AZ, USA
May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA
May 17-May 20: ATS International Conference 2026, Orlando, FL, USA
June 9-June 10: Nasal Drug Delivery Symposium: Current Status and Future Opportunities, Stockholm, Sweden
June 10: SMI.London 2026, London, UK